# NURIX THERAPEUTICS, INC. (NRIX) FY2026 YTD Q3 P&L / Income Statement

- Company: NURIX THERAPEUTICS, INC. (NRIX)
- Period: 2025-12-01 to 2026-08-31
- Filing: Q3 FY2026 10-Q, filed 2026-10-13, accession number 0001549595-26-000049
- Page: https://plicit.ai/financials/nrix/fy2026-ytd-q3-income-statement
- Chart image: https://plicit.ai/charts/nrix-fy2026-ytd-q3-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2025-12-01 through 2026-08-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenue**: 688,359,000 US dollars
- **Total operating expenses**: 315,607,000 US dollars
- **Income (loss) from operations**: 372,752,000 US dollars
- **Other income (expense), net (calculated)**: 13,681,000 US dollars
- **Income (loss) before income taxes**: 386,433,000 US dollars
- **Provision for income taxes**: 13,335,000 US dollars
- **Net income (loss)**: 373,098,000 US dollars
- **Collaboration revenue**: 35,203,000 US dollars
- **License revenue**: 653,156,000 US dollars
- **Total operating expenses**: 315,607,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Arrangement

- Page: https://plicit.ai/financials/nrix/fy2026-ytd-q3-income-statement/revenue-by-arrangement
- Chart image: https://plicit.ai/charts/nrix-fy2026-ytd-q3-revenue-by-arrangement-sankey.png

Income statement for 2025-12-01 through 2026-08-31. View: Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenue**: 688,359,000 US dollars
- **Total operating expenses**: 315,607,000 US dollars
- **Income (loss) from operations**: 372,752,000 US dollars
- **Other income (expense), net (calculated)**: 13,681,000 US dollars
- **Income (loss) before income taxes**: 386,433,000 US dollars
- **Provision for income taxes**: 13,335,000 US dollars
- **Net income (loss)**: 373,098,000 US dollars
- **Sanofi Agreement**: 12,000,000 US dollars
- **Pfizer**: 19,400,000 US dollars
- **Undisclosed (calculated)**: 656,959,000 US dollars
- **Total operating expenses**: 315,607,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.